Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Oct, 2017 | Pages:
60 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Eosinophilic Esophagitis - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Eosinophilic Esophagitis - Pipeline Review, H2 2017, provides an overview of the Eosinophilic Esophagitis (Gastrointestinal) pipeline landscape. Eosinophilic esophagitis is disease characterized by the presence of a large number of a special type of white blood cell, the eosinophil that can cause inflammation in the esophagus. Symptoms include poor weight gain, abdominal pain, nausea, and vomiting, coughing, heartburn and chest pain. Risk factors include weakened immune system, chemotherapy, aspirin and anti-inflammatory medications, chronic vomiting, obesity and alcohol and cigarette use. Treatment includes antiviral, antifungal and pain relievers. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Eosinophilic Esophagitis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Eosinophilic Esophagitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Eosinophilic Esophagitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Eosinophilic Esophagitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Preclinical stages are 2, 4 and 4 respectively. Eosinophilic Esophagitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Eosinophilic Esophagitis (Gastrointestinal). - The pipeline guide reviews pipeline therapeutics for Eosinophilic Esophagitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Eosinophilic Esophagitis (Gastrointestinal) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Eosinophilic Esophagitis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Eosinophilic Esophagitis (Gastrointestinal) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Eosinophilic Esophagitis (Gastrointestinal). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Eosinophilic Esophagitis (Gastrointestinal) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Eosinophilic Esophagitis - Overview 6 Eosinophilic Esophagitis - Therapeutics Development 7 Pipeline Overview 7 Pipeline by Companies 8 Products under Development by Companies 9 Eosinophilic Esophagitis - Therapeutics Assessment 10 Assessment by Target 10 Assessment by Mechanism of Action 12 Assessment by Route of Administration 14 Assessment by Molecule Type 16 Eosinophilic Esophagitis - Companies Involved in Therapeutics Development 18 Adare Pharmaceuticals Inc 18 Calypso Biotech SA 18 Celgene Corp 19 DBV Technologies SA 19 Dr. Falk Pharma GmbH 20 Quorum Innovations LLC 20 Regeneron Pharmaceuticals Inc 21 Shire Plc 21 Eosinophilic Esophagitis - Drug Profiles 22 BPRX-060216 - Drug Profile 22 Product Description 22 Mechanism Of Action 22 R&D Progress 22 budesonide - Drug Profile 23 Product Description 23 Mechanism Of Action 23 R&D Progress 23 budesonide - Drug Profile 27 Product Description 27 Mechanism Of Action 27 R&D Progress 27 CALY-002 - Drug Profile 29 Product Description 29 Mechanism Of Action 29 R&D Progress 29 dupilumab - Drug Profile 30 Product Description 30 Mechanism Of Action 30 R&D Progress 30 fluticasone propionate - Drug Profile 40 Product Description 40 Mechanism Of Action 40 R&D Progress 40 fluticasone propionate - Drug Profile 42 Product Description 42 Mechanism Of Action 42 R&D Progress 42 Qi-201 - Drug Profile 43 Product Description 43 Mechanism Of Action 43 R&D Progress 43 RPC-4046 - Drug Profile 44 Product Description 44 Mechanism Of Action 44 R&D Progress 44 Viaskin Milk - Drug Profile 46 Product Description 46 Mechanism Of Action 46 R&D Progress 46 Eosinophilic Esophagitis - Dormant Projects 49 Eosinophilic Esophagitis - Product Development Milestones 50 Featured News & Press Releases 50 Feb 03, 2017: DBV Technologies Announces Completion of Enrollment of Phase IIA Study of Viaskin Milk for the Treatment of Pediatric Eosinophilic Esophagitis 50 Oct 13, 2016: Celgene to Present New Data on RPC4046 at UEGW and ACG Congresses 50 Sep 21, 2016: DBV Technologies Receives FDA Fast Track Designation for Viaskin Milk for the Treatment of Cows Milk Protein Allergy 51 Jun 13, 2016: Shire Receives FDA Breakthrough Therapy Designation for Investigational Product SHP621 for Rare Gastrointestinal Conditions 51 Nov 12, 2015: DBV Technologies Announces Enrollment of First Patient in Phase IIA Study in Pediatric Eosinophilic Esophagitis 52 Jul 08, 2015: IND Acceptance from FDA for a proof-of-concept trial using Viaskin Milk in Milk-Induced Eosinophilic Esophagitis in Children 52 Oct 03, 2014: Receptos Announces First Patient Treated With Anti-Interleukin-13 Antibody in Phase 2 Trial for Eosinophilic Esophagitis 53 Sep 25, 2014: Meritage Pharma Announces Positive Results of Oral Budesonide Suspension for Treatment of Eosinophilic Esophagitis in Adolescent and Adult Patients 53 Jul 21, 2014: High-dose fluticasone effective against eosinophilic esophagitis 54 May 13, 2014: DBV Technologies Announces Clinical Trial Agreement to Develop a Treatment for Milk-Induced Eosinophilic Esophagitis in Children 55 Aug 13, 2012: Meritage Initiates Clinical Trial Of Oral Budesonide Suspension For Adolescent And Adult Patients With Eosinophilic Esophagitis 55 May 10, 2011: Meritage Pharma Reports Positive Phase IIb Data For Oral Budesonide Suspension In Pediatric Patients With Eosinophilic Esophagitis 56 May 10, 2011: Meritage Reports Positive Phase IIb Data For Oral Budesonide Suspension In Pediatric Patients With Eosinophilic Esophagitis 57 Appendix 59 Methodology 59 Coverage 59 Secondary Research 59 Primary Research 59 Expert Panel Validation 59 Contact Us 59 Disclaimer 60
List of Tables
Number of Products under Development for Eosinophilic Esophagitis, H2 2017 7 Number of Products under Development by Companies, H2 2017 8 Products under Development by Companies, H2 2017 9 Number of Products by Stage and Target, H2 2017 11 Number of Products by Stage and Mechanism of Action, H2 2017 13 Number of Products by Stage and Route of Administration, H2 2017 15 Number of Products by Stage and Molecule Type, H2 2017 17 Eosinophilic Esophagitis - Pipeline by Adare Pharmaceuticals Inc, H2 2017 18 Eosinophilic Esophagitis - Pipeline by Calypso Biotech SA, H2 2017 18 Eosinophilic Esophagitis - Pipeline by Celgene Corp, H2 2017 19 Eosinophilic Esophagitis - Pipeline by DBV Technologies SA, H2 2017 19 Eosinophilic Esophagitis - Pipeline by Dr. Falk Pharma GmbH, H2 2017 20 Eosinophilic Esophagitis - Pipeline by Quorum Innovations LLC, H2 2017 20 Eosinophilic Esophagitis - Pipeline by Regeneron Pharmaceuticals Inc, H2 2017 21 Eosinophilic Esophagitis - Pipeline by Shire Plc, H2 2017 21 Eosinophilic Esophagitis - Dormant Projects, H2 2017 49
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
